# Bone Biology and Fracture Healing

## Bone Structure and Composition

### Macroscopic Architecture

The human skeleton is built from two fundamental types of bone tissue. Cortical (compact) bone accounts for approximately 80% of total skeletal mass and forms the dense outer shell of long bone diaphyses. Its structural unit is the Haversian system, or osteon, which consists of concentric lamellae of bone surrounding a central vascular canal. These osteons are interconnected transversely by Volkmann canals that allow communication between adjacent Haversian systems.

Cancellous (trabecular) bone makes up the remaining 20% of skeletal mass and is found predominantly in the metaphyses and epiphyses of long bones. Its architecture consists of interconnected plates and struts of bone arranged along lines of mechanical stress, consistent with Wolff's law. Because cancellous bone has a much greater surface area relative to its volume, it undergoes more rapid remodeling and plays a more active role in metabolic processes such as calcium homeostasis.

### Microscopic Composition

At the molecular level, bone is a composite material. The organic matrix constitutes roughly 35% of dry bone weight and is composed primarily of Type I collagen (90%), which confers tensile strength. Non-collagenous proteins including osteocalcin, osteopontin, and bone sialoprotein regulate mineralization and cell signaling. The inorganic mineral phase makes up approximately 65% and consists of hydroxyapatite crystals [Ca10(PO4)6(OH)2], which provide compressive strength and rigidity. Water accounts for about 10% of wet bone weight.

### Woven vs. Lamellar Bone

Two histologic patterns of bone organization exist. Woven bone features randomly oriented collagen fibers and is formed rapidly in situations demanding quick structural response, such as fracture callus formation, within tumors, or in Paget disease. Lamellar bone, by contrast, has highly organized parallel collagen fibers, represents mature remodeled bone, and is mechanically superior to woven bone.

| Feature | Woven Bone | Lamellar Bone |
|---------|-----------|---------------|
| Collagen orientation | Random | Organized, parallel |
| Formation rate | Rapid | Slow |
| Mechanical strength | Inferior | Superior |
| Clinical context | Fracture callus, tumors, Paget disease | Mature remodeled bone |
| Cellularity | Higher | Lower |

## Bone Cells and Their Functions

### Osteoblasts

Osteoblasts are the bone-forming cells, derived from mesenchymal stem cells (MSCs). Their primary function is to synthesize osteoid (the unmineralized organic matrix) and subsequently initiate its mineralization. They express characteristic markers including alkaline phosphatase, osteocalcin, and Type I collagen. Differentiation of MSCs into mature osteoblasts requires activation of the Runx2/Cbfa1 transcription factor. Crucially, osteoblasts also regulate bone resorption through their production of RANKL (which stimulates osteoclasts) and OPG (which inhibits them).

### Osteocytes

Osteocytes are terminally differentiated osteoblasts that have become embedded within the mineralized matrix in small spaces called lacunae. They are the most abundant bone cell type, comprising 90-95% of all bone cells. Osteocytes communicate with each other and with surface cells through an extensive network of cytoplasmic processes running through tiny channels called canaliculi. This interconnected network forms the mechanosensing apparatus of bone, allowing the skeleton to detect and respond to mechanical loads. Osteocytes produce sclerostin (encoded by the SOST gene), a protein that inhibits Wnt signaling and thereby suppresses bone formation. This discovery led to the development of romosozumab, an anti-sclerostin antibody used to treat osteoporosis.

### Osteoclasts

Osteoclasts are large, multinucleated cells derived from the monocyte/macrophage lineage (hematopoietic stem cells) whose sole function is to resorb bone. They are activated when RANKL produced by osteoblasts binds to the RANK receptor on osteoclast precursors. Once activated, osteoclasts create resorption pits known as Howship lacunae by secreting hydrogen ions (to dissolve mineral) and cathepsin K (to degrade the organic matrix). Osteoprotegerin (OPG) acts as a decoy receptor that intercepts RANKL before it can bind RANK, thereby reducing osteoclast activity.

### RANK/RANKL/OPG Axis

The RANK/RANKL/OPG system is the central regulatory pathway governing bone remodeling. RANKL promotes osteoclast differentiation, activation, and survival, while OPG counteracts these effects by sequestering RANKL. The balance between RANKL and OPG determines the net rate of bone resorption. When this balance tips toward excess RANKL, the result is excessive resorption and osteoporosis. Conversely, when resorption is deficient (as in genetic OPG overexpression or RANKL deficiency), the result is osteopetrosis with abnormally dense but brittle bone.

## Bone Remodeling

### The Basic Multicellular Unit (BMU)

Bone remodeling is carried out by the basic multicellular unit, a tightly coupled sequence of resorption followed by formation. The full remodeling cycle takes approximately 4-6 months and proceeds through the ARF sequence: Activation, Resorption (lasting 2-4 weeks), Reversal, Formation (lasting 4-6 months), and finally Quiescence. Approximately 10% of the adult skeleton is turned over through this process each year, allowing the skeleton to repair microdamage, adapt to changing mechanical demands, and participate in mineral homeostasis.

### Wolff's Law

Wolff's law states that bone adapts its internal architecture and external form to the mechanical loads placed upon it. Increased loading stimulates bone formation, while decreased loading leads to resorption (disuse osteopenia). This principle has direct clinical relevance in orthopedic surgery: rigid metal implants can shield bone from its normal stresses, leading to localized bone resorption beneath the plate (stress shielding) and potentially increasing refracture risk after implant removal.

## Fracture Healing

### Primary (Direct) Bone Healing

Primary bone healing occurs when a fracture is anatomically reduced and held with absolute stability, typically achieved through compression plating or lag screws. Under these conditions, no callus forms. Instead, healing proceeds through direct osteonal remodeling, where cutting cones of osteoclasts tunnel across the fracture site followed by osteoblasts that deposit new bone. Contact healing occurs when the fracture gap is less than 0.01 mm, allowing direct Haversian remodeling across the interface. Gap healing occurs in slightly larger gaps, where lamellar bone first fills the gap perpendicular to the bone's long axis and is subsequently remodeled into longitudinal osteons.

### Secondary (Indirect) Bone Healing

Secondary healing is the most common physiologic pathway by which fractures unite. It requires relative stability, meaning some controlled micromotion is permitted at the fracture site. This type of healing is seen with splinting, casting, intramedullary nailing, and bridge plating. It proceeds through four overlapping phases.

#### Phase 1: Inflammation (Days 1-7)

The immediate response to fracture is hematoma formation at the fracture site. This hematoma serves as both a structural scaffold and a reservoir of growth factors. Inflammatory cells release cytokines including IL-1, IL-6, and TNF-alpha, which recruit mesenchymal stem cells to the site and initiate angiogenesis. Granulation tissue gradually replaces the hematoma.

#### Phase 2: Soft Callus (Weeks 1-3)

During this phase, recruited progenitor cells undergo chondrogenesis, forming a cartilaginous (soft) callus around the fracture. This represents the initial phase of endochondral ossification. Mechanical stability progressively increases as the soft callus matures. Key growth factors driving this phase include TGF-beta, BMP-2, BMP-7, PDGF, and FGF.

#### Phase 3: Hard Callus (Weeks 3-12)

The cartilaginous callus is progressively mineralized and replaced by woven bone through endochondral ossification. Both periosteal callus (on the outer surface) and endosteal callus (within the medullary canal) bridge the fracture gap. The fracture becomes clinically stable during this phase, though the bone is not yet structurally normal.

#### Phase 4: Remodeling (Months to Years)

In the final phase, basic multicellular units gradually convert the woven bone of the hard callus into mature lamellar bone, restoring the original cortical architecture and recanalization of the medullary canal. This process is guided by Wolff's law, with bone adapting to the functional loads placed upon it. Complete remodeling may take 1-4 years depending on the location, patient age, and mechanical environment.

### The Role of the Periosteum

The periosteum is the single most critical soft tissue structure for secondary bone healing. It consists of two layers: an outer fibrous layer that provides vascular supply and an inner cambium layer rich in osteoprogenitor cells and mesenchymal stem cells. The periosteal callus is the primary driver of indirect fracture healing. Stripping or damaging the periosteum during surgical exposure significantly impairs the healing response. This understanding underlies the development of minimally invasive plate osteosynthesis (MIPO) techniques, which preserve the periosteal blood supply by sliding plates beneath intact soft tissues rather than exposing the fracture site directly.

## Impaired Fracture Healing

### Delayed Union

A delayed union describes a fracture where healing is proceeding more slowly than expected but has not ceased entirely. There is no universally agreed-upon time threshold, but most clinicians consider healing delayed when union has not occurred by 3-6 months depending on the fracture location and pattern.

### Nonunion

A nonunion represents the cessation of biologic healing processes, meaning the fracture will not unite without further intervention. The FDA defines nonunion as a fracture that has not healed at 9 months with no radiographic evidence of progress over the preceding 3 months. Nonunions are classified by their biologic activity.

Hypertrophic nonunions demonstrate adequate biologic response but inadequate mechanical stability. Radiographically, they show exuberant callus formation in an "elephant foot" or "horse hoof" pattern around a persistent fracture gap. Treatment focuses on improving mechanical stability through compression plating or exchange nailing.

Atrophic nonunions have inadequate biology, with minimal or absent callus formation and tapered bone ends. They may also have inadequate stability. Treatment requires both enhancement of the biologic environment (bone grafting, BMP) and provision of stable fixation.

Oligotrophic nonunions represent an intermediate state with some biologic response that is insufficient to achieve union.

| Type | Biology | Stability | Radiographic Appearance | Treatment |
|------|---------|-----------|------------------------|-----------|
| Hypertrophic | Adequate | Inadequate | Exuberant "elephant foot" callus | Improve mechanical stability (compression plating, exchange nailing) |
| Oligotrophic | Insufficient | Variable | Some callus, insufficient bridging | Address both biology and stability |
| Atrophic | Inadequate | Inadequate | Minimal/absent callus, tapered bone ends | Bone grafting/BMP + stable fixation |

### Risk Factors for Nonunion

Patient factors contributing to nonunion include smoking (the single most modifiable risk factor), diabetes, NSAID use, malnutrition, and vitamin D deficiency. Fracture-related factors include open fractures, comminution, segmental bone loss, and infection. Treatment-related factors include inadequate fixation, excessive periosteal stripping during surgery, and distraction at the fracture site.

### Workup for Nonunion

Evaluating a nonunion requires a systematic approach. An infection screen (ESR, CRP, WBC, and aspiration if there is clinical concern) should be performed, as occult infection is a commonly missed cause. A metabolic workup including calcium, phosphate, vitamin D, PTH, thyroid function, and albumin identifies correctable metabolic contributors. CT scanning assesses the degree of bridging callus and characterizes the fracture gap. Implant integrity and fixation stability must also be evaluated.

## Bone Grafting and Biologics

| Graft Type | Osteoconductive | Osteoinductive | Osteogenic | Key Advantages | Key Disadvantages |
|-----------|----------------|----------------|-----------|----------------|-------------------|
| Autograft (iliac crest, RIA) | Yes | Yes | Yes | Gold standard; provides all three elements | Donor site morbidity |
| Allograft (structural/cancellous) | Yes | No | No | No donor site morbidity; available in bulk | No viable cells; disease transmission risk |
| BMP-2 / BMP-7 | No | Yes | No | Potent osteoinduction; FDA-approved indications | HO, swelling, cost, carcinogenicity concerns |
| Demineralized Bone Matrix (DBM) | Yes | Yes (variable) | No | Combined properties; off-the-shelf | Variable biologic activity |

### Autograft

Autologous bone graft remains the gold standard because it uniquely provides all three elements needed for bone formation: an osteoconductive scaffold, osteoinductive growth factors, and viable osteogenic cells. The iliac crest is the most common harvest site. The reamer-irrigator-aspirator (RIA) system allows high-volume graft harvest from the femoral canal as an alternative. Donor site morbidity (pain, hematoma, infection, and nerve injury) remains the primary disadvantage.

### Allograft

Allograft bone provides an osteoconductive scaffold but contains no viable osteogenic cells due to processing. It is available as structural grafts (cortical struts for mechanical support) or cancellous chips (morselized for filling defects). The risk of disease transmission is extremely low with modern processing techniques.

### Bone Morphogenetic Proteins (BMPs)

BMP-2 and BMP-7 are potent osteoinductive growth factors that can induce bone formation even in ectopic sites. They are FDA-approved for specific indications including open tibial fractures and spinal fusion. Off-label use has become widespread but remains controversial because of associated complications including heterotopic ossification, significant soft tissue swelling, and theoretical concerns about carcinogenicity.

### Demineralized Bone Matrix (DBM)

DBM is produced by acid extraction of allograft bone, which removes the mineral component while retaining the collagen scaffold and endogenous growth factors including BMPs. It provides both osteoinductive and osteoconductive properties. However, the biologic activity of DBM products is variable depending on processing methods and donor characteristics.

<image>A detailed medical illustration showing the four phases of secondary (indirect) fracture healing in a long bone cross-section. Phase 1 shows the fracture hematoma with inflammatory cells. Phase 2 shows soft cartilaginous callus forming around the fracture site. Phase 3 shows hard callus with woven bone replacing cartilage. Phase 4 shows remodeled lamellar bone with restored cortical architecture. Each phase is labeled with key cellular and molecular events.</image>

<image>A diagram of the RANK/RANKL/OPG signaling axis. Show an osteoblast producing both RANKL and OPG. RANKL binds to RANK receptor on an osteoclast precursor, promoting differentiation into a mature multinucleated osteoclast that resorbs bone. OPG acts as a decoy receptor intercepting RANKL. Include labels for all molecular components and the downstream effects on bone resorption.</image>

<image>A comparative illustration of primary (direct) vs. secondary (indirect) bone healing. On the left, show a fracture fixed with a compression plate achieving anatomic reduction and direct osteonal remodeling with cutting cones — no visible callus. On the right, show a fracture treated with an intramedullary nail allowing controlled micromotion, with robust periosteal and endosteal callus formation via endochondral ossification.</image>

<image>A medical illustration showing hypertrophic vs. atrophic nonunion on radiographic appearance. On the left, a hypertrophic nonunion with abundant "elephant foot" callus around a fracture with a visible gap — indicating biologic activity but mechanical instability. On the right, an atrophic nonunion with minimal callus, tapered bone ends, and a clear persistent fracture line — indicating biologic failure. Label key features of each type.</image>

## Clinical Pearls

Smoking is the single most modifiable risk factor for nonunion, making cessation counseling an essential part of the surgical intervention. The periosteum is the most important soft tissue structure for fracture healing and should be preserved during surgical approaches whenever possible. Understanding the distinction between hypertrophic and atrophic nonunion guides treatment: hypertrophic nonunion is fundamentally a mechanical problem requiring improved stability, while atrophic nonunion is a biologic problem requiring graft or biologics to restart the healing cascade. Primary bone healing demands both absolute stability and anatomic reduction; if either condition is not met, the surgeon should expect secondary healing with callus formation. The fracture hematoma should not be routinely evacuated, as it serves as a critical growth factor reservoir that initiates the healing cascade. NSAIDs can impair fracture healing and should be avoided during the healing window, particularly in patients with other risk factors for nonunion. BMP-2 is a powerful osteoinductive agent but carries real risks including heterotopic ossification and soft tissue swelling. Finally, vitamin D deficiency is highly prevalent in fracture patients and should be screened for and corrected as part of a comprehensive treatment plan.

## References

- Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and interventions. *Nat Rev Rheumatol*. 2015;11(1):45-54.
- Marsell R, Einhorn TA. The biology of fracture healing. *Injury*. 2011;42(6):551-555.
- Giannoudis PV, Einhorn TA, Marsh D. Fracture healing: the diamond concept. *Injury*. 2007;38 Suppl 4:S3-6.
- Calori GM, et al. The use of bone-graft substitutes in large bone defects: any specific needs? *Injury*. 2011;42 Suppl 2:S56-63.
- AAOS Clinical Practice Guidelines on Metabolic and Endocrine Effects on Fracture Healing.